Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
13
04
2023
accepted:
23
05
2023
medline:
16
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
Carbapenem-resistant We report a case of severe infection by CRAB resistant to both colistin and cefiderocol treated with sulbactam/durlobactam and describe the molecular features of the strain. Susceptibility to cefiderocol was detected by disc diffusion according to EUCAST breakpoints. Susceptibility to sulbactam/durlobactam was determined by Etest according to preliminary breakpoints provided by Entasis Therapeutics. Whole Genome Sequencing (WGS) of the CRAB isolate was performed. A burn patient with ventilator-associated pneumonia by CRAB resistant to colistin and cefiderocol received sulbactam/durlobactam as compassionate use. She was alive after 30 days from the end of therapy. Complete microbiological eradication of CRAB was achieved. The isolate harboured Further treatment options for severe infections by CRAB resistant to all available antibiotics are urgently needed. Sulbactam/durlobactam may be a future option against MDR
Sections du résumé
Background
UNASSIGNED
Carbapenem-resistant
Methods
UNASSIGNED
We report a case of severe infection by CRAB resistant to both colistin and cefiderocol treated with sulbactam/durlobactam and describe the molecular features of the strain. Susceptibility to cefiderocol was detected by disc diffusion according to EUCAST breakpoints. Susceptibility to sulbactam/durlobactam was determined by Etest according to preliminary breakpoints provided by Entasis Therapeutics. Whole Genome Sequencing (WGS) of the CRAB isolate was performed.
Results
UNASSIGNED
A burn patient with ventilator-associated pneumonia by CRAB resistant to colistin and cefiderocol received sulbactam/durlobactam as compassionate use. She was alive after 30 days from the end of therapy. Complete microbiological eradication of CRAB was achieved. The isolate harboured
Conclusions
UNASSIGNED
Further treatment options for severe infections by CRAB resistant to all available antibiotics are urgently needed. Sulbactam/durlobactam may be a future option against MDR
Identifiants
pubmed: 37325251
doi: 10.1093/jacamr/dlad078
pii: dlad078
pmc: PMC10265591
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlad078Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
JAC Antimicrob Resist. 2020 Aug 25;2(3):dlaa060
pubmed: 34223017
Biomed Res Int. 2018 May 10;2018:6976923
pubmed: 29862284
Ann Transl Med. 2022 Mar;10(5):261
pubmed: 35402576
PLoS One. 2010 Apr 07;5(4):e10034
pubmed: 20383326
Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011
pubmed: 32042848
Lancet Infect Dis. 2023 May 11;:
pubmed: 37182534
Antimicrob Agents Chemother. 2022 May 17;66(5):e0214221
pubmed: 35311522
Open Forum Infect Dis. 2022 Mar 05;9(4):ofac092
pubmed: 35350174
JAC Antimicrob Resist. 2021 Nov 17;3(4):dlab174
pubmed: 34806011
J Glob Antimicrob Resist. 2022 Mar;28:120-124
pubmed: 34958997
J Glob Antimicrob Resist. 2020 Sep;22:738-741
pubmed: 32702396
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0078122
pubmed: 36005804
Infect Dis Ther. 2021 Dec;10(4):2177-2202
pubmed: 34648177
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024
pubmed: 32941593
Lancet Infect Dis. 2021 Feb;21(2):226-240
pubmed: 33058795
Clin Infect Dis. 2023 Jun 16;76(12):2059-2069
pubmed: 36801828
Int J Antimicrob Agents. 2022 Aug;60(2):106611
pubmed: 35697179
Lancet Infect Dis. 2018 Apr;18(4):391-400
pubmed: 29456043
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0087721
pubmed: 34252309
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0092421
pubmed: 34370576
Clin Infect Dis. 2023 Feb 8;76(3):e1261-e1265
pubmed: 35974429